Adrenocortical carcinoma classification: Difference between revisions
No edit summary |
Mchitsazan (talk | contribs) No edit summary |
||
(9 intermediate revisions by 5 users not shown) | |||
Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}} | {{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Adrenocortical carcinoma | Adrenocortical carcinoma can be classified according to [[hormone]] production, and [[histological]] appearance. ACC may secrete [[cortisol]], [[aldosterone]], [[testosterone]] or [[estrogen]]. Other variants include oncocytic adrenal cortical carcinoma, myxoid adrenal cortical carcinoma, and carcinosarcoma. According to the [[TNM staging system]], there are four stages of adrenocortical cancer based on the [[tumor]] size, [[lymph nodes]], and distant [[metastasis]]. Each stage is assigned a number and letter that designates the number of [[lymph nodes]] involved and presence/absence of [[Metastasis|distant metastasis]]. | ||
==Classification== | ==Classification== | ||
[[Adrenocortical carcinoma]]s are classified | [[Adrenocortical carcinoma]]s are classified based on:<ref name="pmid22086150">{{cite journal| author=de Krijger RR, Papathomas TG| title=Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. | journal=Virchows Arch | year= 2012 | volume= 460 | issue= 1 | pages= 9-18 | pmid=22086150 | doi=10.1007/s00428-011-1166-y | pmc=3267029 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22086150 }}</ref> | ||
===Hormones production=== | ===Hormones production:=== | ||
==== Functional ==== | |||
A Functional adrenocortical carcinoma may produce one or more of the following [[hormones]]:<ref name="pmid23169720">{{cite journal| author=Ganeshan D, Bhosale P, Kundra V| title=Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: what radiologists should know. | journal=AJR Am J Roentgenol | year= 2012 | volume= 199 | issue= 6 | pages= 1283-93 | pmid=23169720 | doi=10.2214/AJR.11.8282 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23169720 }}</ref> | |||
:*[[Cortisol]] | :*[[Cortisol]] | ||
:*[[Aldosterone]] | :*[[Aldosterone]] | ||
:*[[Testosterone]] | :*[[Testosterone]] | ||
:*[[Estrogen]] | :*[[Estrogen]] | ||
==== Nonfunctional ==== | |||
===Histology=== | A nonfunctional adrenocortical carcinoma does not procuce any of the above hormones. | ||
===Histology:=== | |||
Adrenocortical carcinoma can be classified according to the differentiation of the tissue under the microscope into: | |||
* Well-differentiated | * Well-differentiated | ||
* Intermediate differentiated | * Intermediate differentiated | ||
Line 23: | Line 28: | ||
* [[Anaplastic]] | * [[Anaplastic]] | ||
===Variants=== | ===Variants:=== | ||
* Oncocytic adrenal cortical carcinoma | * Oncocytic adrenal cortical carcinoma | ||
* Myxoid adrenal cortical carcinoma | * Myxoid adrenal cortical carcinoma | ||
Line 29: | Line 34: | ||
* [[Adenosquamous carcinoma|Adenosquamous]] adrenocortical carcinoma | * [[Adenosquamous carcinoma|Adenosquamous]] adrenocortical carcinoma | ||
* [[Clear cell tumor|Clear cell]] adrenal cortical carcinoma | * [[Clear cell tumor|Clear cell]] adrenal cortical carcinoma | ||
==Staging of adrenocortical carcinoma== | |||
The AJCC has designated staging by [[TNM Staging System|TNM]] to define adrenocortical carcinoma: <ref name="pmid20180029">{{cite journal| author=Edge SB, Compton CC| title=The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | journal=Ann Surg Oncol | year= 2010 | volume= 17 | issue= 6 | pages= 1471-4 | pmid=20180029 | doi=10.1245/s10434-010-0985-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20180029 }}</ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Adrenal cancer TNM staging''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
! style="background: #DCDCDC;" |TX | |||
! style="background: #F5F5F5;" |Primary [[tumor]] cannot be assessed | |||
|- | |||
! style="background: #DCDCDC;" |T0 | |||
! style="background: #F5F5F5;" |No evidence of primary [[tumor]] | |||
|- | |||
! style="background: #DCDCDC;" |T1 | |||
! style="background: #F5F5F5;" |[[Tumor]] ≤5 cm in greatest dimension limited to the [[thyroid|adrenals]] | |||
|- | |||
! style="background: #DCDCDC;" |T2 | |||
! style="background: #F5F5F5;" |[[Tumor]] >5 cm in greatest dimension, limited to the adrenals | |||
|- | |||
! style="background: #DCDCDC;" |T3 | |||
! style="background: #F5F5F5;" |Tumor of any size with local invasion, but not invading adjacent organs | |||
|- | |||
! style="background: #DCDCDC;" |T4 | |||
! style="background: #F5F5F5;" |Tumor of any size with invasion of adjacent organs | |||
|} | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Regional Lymph Nodes (N)''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
! style="background: #DCDCDC;" |NX | |||
! style="background: #F5F5F5;" |Regional [[lymph node]] cannot be assessed | |||
|- | |||
! style="background: #DCDCDC;" |N0 | |||
! style="background: #F5F5F5;" |No regional lymph node metastasis | |||
|- | |||
! style="background: #DCDCDC;" |N1 | |||
! style="background: #F5F5F5;" |Regional [[lymph node]] metastasis | |||
|} | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Distant Metastasis (M)''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
! style="background: #DCDCDC;" |M0 | |||
! style="background: #F5F5F5;" |No distant [[metastasis]] | |||
|- | |||
! style="background: #DCDCDC;" |M1 | |||
! style="background: #F5F5F5;" |Distant [[metastasis]] | |||
|} | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Anatomic Stage/Prognostic Groups''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|T}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|N}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|M}} | |||
|- | |||
! style="background: #DCDCDC;" |I | |||
! style="background: #F5F5F5;" |T1 | |||
! style="background: #F5F5F5;" |N0 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" |II | |||
! style="background: #F5F5F5;" |T2 | |||
! style="background: #F5F5F5;" |N0 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" |III | |||
! style="background: #F5F5F5;" |T1 | |||
! style="background: #F5F5F5;" |N1 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" | | |||
! style="background: #F5F5F5;" |T2 | |||
! style="background: #F5F5F5;" |N1 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" | | |||
! style="background: #F5F5F5;" |T3 | |||
! style="background: #F5F5F5;" |N0 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" |IV | |||
! style="background: #F5F5F5;" |T3 | |||
! style="background: #F5F5F5;" |N1 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! | |||
!T4 | |||
!N0 | |||
!M0 | |||
|- | |||
! | |||
!T4 | |||
!N1 | |||
!M0 | |||
|- | |||
! | |||
!Any T | |||
!Any N | |||
!M1 | |||
|} | |||
A new study showed staging system that incorporates the patient's age better and predicts 5-year survival among patients with stages I/II ACC. Consideration should be given to include age in staging for ACC, because it may better inform providers about treatment and prognosis.<ref name="pmid25456914">{{cite journal| author=Asare EA, Wang TS, Winchester DP, Mallin K, Kebebew E, Sturgeon C| title=A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. | journal=Surgery | year= 2014 | volume= 156 | issue= 6 | pages= 1378-85; discussion 1385-6 | pmid=25456914 | doi=10.1016/j.surg.2014.08.018 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25456914 }}</ref> | |||
==References== | ==References== |
Latest revision as of 18:34, 24 October 2019
Adrenocortical carcinoma Microchapters |
Differentiating Adrenocortical carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Study |
Adrenocortical carcinoma classification On the Web |
American Roentgen Ray Society Images of Adrenocortical carcinoma classification |
Risk calculators and risk factors for Adrenocortical carcinoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3] Mohammed Abdelwahed M.D[4]
Overview
Adrenocortical carcinoma can be classified according to hormone production, and histological appearance. ACC may secrete cortisol, aldosterone, testosterone or estrogen. Other variants include oncocytic adrenal cortical carcinoma, myxoid adrenal cortical carcinoma, and carcinosarcoma. According to the TNM staging system, there are four stages of adrenocortical cancer based on the tumor size, lymph nodes, and distant metastasis. Each stage is assigned a number and letter that designates the number of lymph nodes involved and presence/absence of distant metastasis.
Classification
Adrenocortical carcinomas are classified based on:[1]
Hormones production:
Functional
A Functional adrenocortical carcinoma may produce one or more of the following hormones:[2]
Nonfunctional
A nonfunctional adrenocortical carcinoma does not procuce any of the above hormones.
Histology:
Adrenocortical carcinoma can be classified according to the differentiation of the tissue under the microscope into:
- Well-differentiated
- Intermediate differentiated
- Poorly differentiated
- Anaplastic
Variants:
- Oncocytic adrenal cortical carcinoma
- Myxoid adrenal cortical carcinoma
- Carcinosarcoma
- Adenosquamous adrenocortical carcinoma
- Clear cell adrenal cortical carcinoma
Staging of adrenocortical carcinoma
The AJCC has designated staging by TNM to define adrenocortical carcinoma: [3]
Stage | Description |
---|---|
TX | Primary tumor cannot be assessed |
T0 | No evidence of primary tumor |
T1 | Tumor ≤5 cm in greatest dimension limited to the adrenals |
T2 | Tumor >5 cm in greatest dimension, limited to the adrenals |
T3 | Tumor of any size with local invasion, but not invading adjacent organs |
T4 | Tumor of any size with invasion of adjacent organs |
Stage | Description |
---|---|
NX | Regional lymph node cannot be assessed |
N0 | No regional lymph node metastasis |
N1 | Regional lymph node metastasis |
Stage | Description |
---|---|
M0 | No distant metastasis |
M1 | Distant metastasis |
Stage | T | N | M |
---|---|---|---|
I | T1 | N0 | M0 |
II | T2 | N0 | M0 |
III | T1 | N1 | M0 |
T2 | N1 | M0 | |
T3 | N0 | M0 | |
IV | T3 | N1 | M0 |
T4 | N0 | M0 | |
T4 | N1 | M0 | |
Any T | Any N | M1 |
A new study showed staging system that incorporates the patient's age better and predicts 5-year survival among patients with stages I/II ACC. Consideration should be given to include age in staging for ACC, because it may better inform providers about treatment and prognosis.[4]
References
- ↑ de Krijger RR, Papathomas TG (2012). "Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants". Virchows Arch. 460 (1): 9–18. doi:10.1007/s00428-011-1166-y. PMC 3267029. PMID 22086150.
- ↑ Ganeshan D, Bhosale P, Kundra V (2012). "Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: what radiologists should know". AJR Am J Roentgenol. 199 (6): 1283–93. doi:10.2214/AJR.11.8282. PMID 23169720.
- ↑ Edge SB, Compton CC (2010). "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM". Ann Surg Oncol. 17 (6): 1471–4. doi:10.1245/s10434-010-0985-4. PMID 20180029.
- ↑ Asare EA, Wang TS, Winchester DP, Mallin K, Kebebew E, Sturgeon C (2014). "A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease". Surgery. 156 (6): 1378–85, discussion 1385-6. doi:10.1016/j.surg.2014.08.018. PMID 25456914.